Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-gvh9x Total loading time: 0 Render date: 2024-07-19T14:24:12.306Z Has data issue: false hasContentIssue false

7 - Therapeutic decision making in BMT/SCT for myelodysplasia

Published online by Cambridge University Press:  05 August 2013

By
Carolina Escobar ,
Reinhold Munker  and
Kerry Atkinson
Edited by
Reinhold Munker ,
Gerhard C. Hildebrandt ,
Hillard M. Lazarus  and
Kerry Atkinson
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Gerhard C. Hildebrandt
Affiliation:
University of Utah
Hillard M. Lazarus
Affiliation:
Ireland Cancer Center, Case Western Reserve University Hospital, Cleveland
Kerry Atkinson
Affiliation:
University of Queensland
Get access

Summary

MDS constitutes a group of clonal hematopoietic stem cell disorders occurring often in the elderly that are characterized by cytopenias and cytogenetic abnormalities, and can evolve into AML. The prevalence and incidence of MDS have increased in the last 20 years, likely as a result of increasing longevity of the population. These disorders are heterogeneous and staged and classified according to the percentage of blasts in the bone marrow, cytogenetic abnormalities, and number of cytopenias. As shown on pages 78–79, several staging systems are available. The International Prognostic Scoring System (IPSS) will divide cases of MDS into groups according to survival and risk for leukemia transformation. The disadvantage of this scoring system is that it does not take into account age, ferritin, transfusion dependence, and marrow fibrosis. There are other scoring systems like the WHO Prognostic Scoring System for OS and relapse. A revised scoring system is currently under development (Appelbaum et al., 2011).

Type
Chapter
Information
The BMT Data Book
Including Cellular Therapy
 , pp. 77 - 89
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Appelbaum, FR. 2011. The role of hematopoietic cell transplantation as therapy for myelodysplasia. Best Pract Res Clin Hematol 24: 541–547.CrossRefGoogle ScholarPubMed
Cutler, CS, Lee, SJ, Greenberg, P, et al. 2004. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104: 579–585.CrossRefGoogle ScholarPubMed
Deeg, HJ, Storer, B, Slattery, JT, et al. 2002. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100: 1201–1207.CrossRefGoogle ScholarPubMed
Deschler, B, de Witte, T, Mertelsmann, R, et al. 2006. Decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91: 1513–1522.Google ScholarPubMed
De Witte, T, Brand, R, van Biezen, A, et al. 2006. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. Haematologica 91: 750–756.Google ScholarPubMed
Fenaux, P, Mufti, GJ, Hellstrom-Lindberg, E, et al. 2009. Efficacy of azacitidine compared with that of higher risk myelodysplastic syndromes: a randomized, open label phase III study. Lancet Oncol 10: 223–232.CrossRefGoogle ScholarPubMed
Greenberg, P, Cox, C, Lebeau, MM, et al. 1997. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079–2088.Google ScholarPubMed
Hofmann, WK & Koeffler, HP. 2005. Myelodysplastic syndrome. Annu Rev Med 56: 1–16.CrossRefGoogle ScholarPubMed
Ingram, W, Lim, ZY, & Mufti, GJ. 2007. Allogeneic transplantation for myelodysplastic syndrome (MDS). Blood Rev 21: 61–71.CrossRefGoogle Scholar
List, A, Dewald, G, Bennett, J, et al. 2006. Lenalidomide in the myelodysplastic syndrome with chromosome 5 q deletion. N Engl J Med 355: 1456–1465.CrossRefGoogle Scholar
Martino, R, Iacobelli, S, Brand, R, et al. 2006. Retrospective comparison of reduced intensity conditioning and conventional high-dose conditioning for allogeneic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108: 836–846.CrossRefGoogle ScholarPubMed
Olney, HJ & LeBeau, MM. 2007. Evaluation of recurrent cytogenetic abnormalities in the treatment of myelodysplastic syndromes. Leuk Res 31: 427–434.CrossRefGoogle Scholar
Parmar, S, de Lima, M, Deeg, HJ, et al. 2011. Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. Sem Oncol 38: 693–704.CrossRefGoogle ScholarPubMed
Platzbecker, U, Wermke, M, Radke, J, et al. 2011. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26: 381–389.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×